Literature DB >> 12764137

MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine.

Yanping Guo1, Elena Kotova, Zhe-Sheng Chen, Kun Lee, Elizabeth Hopper-Borge, Martin G Belinsky, Gary D Kruh.   

Abstract

MRP8 (ABCC11) is a recently identified cDNA that has been assigned to the multidrug resistance-associated protein (MRP) family of ATP-binding cassette transporters, but its functional characteristics have not been determined. Here we examine the functional properties of the protein using transfected LLC-PK1 cells. It is shown that ectopic expression of MRP8 reduces basal intracellular levels of cAMP and cGMP and enhances cellular extrusion of cyclic nucleotides in the presence or absence of stimulation with forskolin or SIN-1A. Analysis of the sensitivity of MRP8-overexpressing cells revealed that they are resistant to a range of clinically relevant nucleotide analogs, including the anticancer fluoropyrimidines 5'-fluorouracil (approximately 3-fold), 5'-fluoro-2'-deoxyuridine (approximately 5-fold), and 5'-fluoro-5'-deoxyuridine (approximately 3-fold), the anti-human immunodeficiency virus agent 2',3'-dideoxycytidine (approximately 6-fold) and the anti-hepatitis B agent 9'-(2'-phosphonylmethoxynyl)adenine (PMEA) (approximately 5-fold). By contrast, increased resistance was not observed for several natural product chemotherapeutic agents. In accord with the notion that MRP8 functions as a drug efflux pump for nucleotide analogs, MRP8-transfected cells exhibited reduced accumulation and increased efflux of radiolabeled PMEA. In addition, it is shown by the use of in vitro transport assays that MRP8 is able to confer resistance to fluoropyrimidines by mediating the MgATP-dependent transport of 5'-fluoro-2'-deoxyuridine monophosphate, the cytotoxic intracellular metabolite of this class of agents, but not of 5'-fluorouracil or 5'-fluoro-2'-deoxyuridine. We conclude that MRP8 is an amphipathic anion transporter that is able to efflux cAMP and cGMP and to function as a resistance factor for commonly employed purine and pyrimidine nucleotide analogs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764137     DOI: 10.1074/jbc.M304059200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  ABC transporters and their role in nucleoside and nucleotide drug resistance.

Authors:  Yu Fukuda; John D Schuetz
Journal:  Biochem Pharmacol       Date:  2012-01-20       Impact factor: 5.858

Review 2.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

3.  The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells.

Authors:  David A Plotnik; Lena J McLaughlin; Jenny Chan; Joshua N Redmayne-Titley; Jeffrey L Schwartz
Journal:  Nucl Med Biol       Date:  2011-06-22       Impact factor: 2.408

4.  Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Authors:  Shuiying Hu; Hongmei Niu; Hiroto Inaba; Shelley Orwick; Charles Rose; John C Panetta; Shengping Yang; Stanley Pounds; Yiping Fan; Christopher Calabrese; Jerold E Rehg; Dario Campana; Jeffrey E Rubnitz; Sharyn D Baker
Journal:  J Natl Cancer Inst       Date:  2011-04-12       Impact factor: 13.506

5.  Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.

Authors:  Sabrina Copsel; Corina Garcia; Federico Diez; Monica Vermeulem; Alberto Baldi; Liliana G Bianciotti; Frans G M Russel; Carina Shayo; Carlos Davio
Journal:  J Biol Chem       Date:  2011-01-04       Impact factor: 5.157

6.  Dependence of multidrug resistance protein-mediated cyclic nucleotide efflux on the background sodium conductance.

Authors:  Marek Kucka; Karla Kretschmannova; Takayo Murano; Chung-Pu Wu; Hana Zemkova; Suresh V Ambudkar; Stanko S Stojilkovic
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

7.  Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway.

Authors:  T Chiavegatti; V L Costa; M S Araújo; R O Godinho
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

8.  Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.

Authors:  Z Ping Lin; Yong-Lian Zhu; Dennis R Johnson; Kevin P Rice; Timothy Nottoli; Bryan C Hains; James McGrath; Stephen G Waxman; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2007-10-24       Impact factor: 4.436

Review 9.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

10.  Hypotonic cell swelling stimulates permeability to cAMP in a rat colonic cell line.

Authors:  P E Golstein; A Daifi; R Crutzen; A Boom; W Van Driessche; R Beauwens
Journal:  Pflugers Arch       Date:  2004-01-16       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.